Executive Summary Amicus Therapeutics (NASDAQ: FOLD) has transformed from a venture-backed rare disease startup into a profitable commercial-stage company with

As 2025 draws to a close, three major oncology conferences delivered substantial clinical trial data that will inform treatment decisions

The veterinary pharmaceutical sector generated an estimated $650 million to $975 million in annual royalty flows in 2024, representing approximately

The question of where to take a biotech company public has never carried higher stakes. In 2025, the transatlantic divide

The week of December 8-13, 2025 delivered extraordinary capital formation across biopharma, with $3.2 billion in follow-on offerings sold

Biotech deal announcements routinely trumpet eye-catching "biobucks" figures—billions promised in future milestone payments if all goes well.

A Dallas-based specialty lender approaches a pivotal moment as it prepares to merge with Runway Growth Finance, marking the end of an era for one of healthcare credit's most specialized players.

Terray Therapeutics has assembled what may be the largest proprietary chemistry dataset in drug discovery—13+ billion target-molecule binding measurements, growing at 1 billion per quarter. The Los Angeles-based company has raised over $200 million.

The Volume Trap: Why Diagnostic Royalties Don't Compound Royalty financing has become a cornerstone of life sciences capital

Biotech ETFs surge in 2025 as sector emerges from nuclear funding winter. XBI +37%, ARKG +43%, IBB +30%—all crushing the S&P 500. Big Pharma's $176B patent cliff drives M&A frenzy with 100%+ premiums. Fund flows turn positive for first time since 2021. Is the biotech winter finally over?